Ann: Half Yearly Report and Accounts, page-41

We are not starting from scratch, we are just priced that way. In theory the inflection point hasn't altered at all assuming Cohort 4 works or is a significant leap from Cohort 3. They turned a logical business decision into a PR disaster. They had never spoken about HCV pharma deals and none of us were expecting it. Everyone wants a HBV deal.

They have put the phone off the hook as I have tried calling 6 times this afternoon and the answering machine says 'go away'.

Its all about HBV but they were proceeding with that and Cohort 4 anyway and didn't have trash the stock today. What was achieved other than convince a number of shareholders that their program doesn't work, efficacy is a myth, or inflection points will be pushed back years creating the biggest rush for the exit we have ever seen. That is a PR disaster and confirms the entire board is inadequate and the now permanent PR resident Annabel actually understands or contributes very little.